FGP
AGIO icon

Freestone Grove Partners’s Agios Pharmaceuticals AGIO Stock Holding History

Freestone Grove Partners’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-40,841
Closed -$1.11M – 971
2025
Q4 		$1.11M Buy
40,841
+25,417
+165% +$892K 0.01% 456
2025
Q3 		$619K Buy
+15,424
New +$580K ﹤0.01% 505

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Freestone Grove Partners's AGIO Position: Q1 2026 in Review

Freestone Grove Partners sold out of Agios Pharmaceuticals (AGIO) in Q1 2026, closing a stake of 40,841 shares — an estimated $1.11M sold.

Freestone Grove Partners first reported a position in AGIO in Q3 2025 and held it in 2 quarters. The position peaked at $1.11M in Q4 2025. 234 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

  • Freestone Grove Partners reported no remaining Agios Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 40,841 Agios Pharmaceuticals shares in Q1 2026, an estimated $1.11M.
  • Freestone Grove Partners first reported a position in Agios Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Freestone Grove Partners's Agios Pharmaceuticals position peaked at $1.11M in Q4 2025.
  • 234 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.